Alnylam Pharmaceuticals
ALNY
356 hedge funds and large institutions have $15.8B invested in Alnylam Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 125 increasing their positions, 129 reducing their positions, and 49 closing their positions.
3% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 129
5% less capital invested
Capital invested by funds: $16.5B → $15.8B (-$744M)
7% less call options, than puts
Call options by funds: $121M | Put options by funds: $131M
3.68% less ownership
Funds ownership: 97.24% → 93.55% (-3.7%)
5% less funds holding
Funds holding: 374 → 356 (-18)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
35% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 49
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.1M |
| 2 |
Goldman Sachs
New York
|
-$70.7M |
| 3 |
SPC
Slate Path Capital
New York
|
-$52.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.5M |
ALNY Hedge Fund Activity: Q3 2020 in Review
356 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2020, worth a combined $15.8B — down 4.5% from $16.5B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ALNY and 32 opened new positions — a net loss of 17 holders — while 129 trimmed existing stakes and 125 added.
The largest buyer was Massachusetts Financial Services, adding an estimated $120M. The largest seller was Fidelity Investments, cutting an estimated $86.1M.
- 356 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2020, down from 374 in Q2 2020.
- Funds reported $15.8B of Alnylam Pharmaceuticals stock for Q3 2020, down 4.5% quarter-over-quarter.
- 32 funds opened new Alnylam Pharmaceuticals positions in Q3 2020 and 49 closed out, a net change of -17 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2020 was Massachusetts Financial Services, an estimated $120M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $86.1M sold.
Based on aggregated 13F filings for Q3 2020.